Clairity, a breast imaging AI startup, secured $43M to advance its FDA-cleared mammogram risk prediction tool.
Key Details
- 1Clairity, founded in 2020 by radiologist Dr. Constance Lehman, raised $43 million in Series B funding.
- 2Major investors include Ace Global Equity, Santé Ventures, and the Breast Cancer Research Foundation.
- 3The AI tool predicts five-year breast cancer risk from routine mammograms.
- 4Clairity Breast received FDA de novo authorization in May 2024.
- 5The funds will support commercialization and expanding partnerships.
Why It Matters
This funding enables broader access to AI-driven breast cancer risk prediction using standard mammography, potentially improving early detection and risk stratification. Widespread adoption could reshape preventive strategies and workflow in breast imaging practices.
Source
Radiology Business
Related News
•AuntMinnie
MRI Integration Enhances Multimodal AI for Breast Cancer Risk and Detection
Adding MRI to a multimodal AI model significantly improves breast cancer detection and risk prediction.
•Cardiovascular Business
AI Model Dramatically Enhances Severe Heart Attack Detection via ECGs
Queen of Hearts AI model outperforms standard care in detecting severe heart attacks from ECGs.
•AuntMinnie
AI-CAD Demonstrates High Sensitivity in Breast Cancer Screening
A large study found that AI-based computer-aided detection (AI-CAD) can improve breast cancer detection and support radiologists in screening mammography.